ClinicalTrials.gg
Sign In

Paraganglioma clinical trials

The registry lists 107 studies for Paraganglioma across more than 10 countries. 48 are recruiting or about to start. 9 of them are mainly about Paraganglioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Pheochromocytoma too: 174 studies, 62 open.

Get an email when these change. Save the Paraganglioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
36
Completed
25
Terminated
9
Active, not recruiting
8
Status unknown
8
Not yet recruiting
8

Phase

Phase 2
45
Phase 1
15
Phase 4
3
Phase 3
3
Early Phase 1
2

Where

United States
49
China
16
France
15
Italy
7
Canada
7
Netherlands
7

Who runs them

National Cancer Institute (NCI) (12) · Peking Union Medical College Hospital (9) · Molecular Insight Pharmaceuticals, Inc. (5) · M.D. Anderson Cancer Center (4) · Assistance Publique - Hôpitaux de Paris (4) · University of California, San Francisco (4) · British Columbia Cancer Agency (4) · Nanjing First Hospital, Nanjing Medical University (2)

What is being tested here

Drugs under test in Paraganglioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Belzutifan404
Lead PB-212303
Lutetium Lu 177 dotatate104
Olaparib102
Temozolomide102
Gallium Ga 68 dotatate102
177Lu-octreotide, DOTA(0)-Tyr(3)-102
Florbenguane F-18102
Ivonescimab101
Zanzalintinib101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Immune checkpoint inhibitors 1 open

Coming up

0phase 3 studies under way
10studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10

Who these studies take

Of the 36 Paraganglioma studies recruiting now, 21 (58%) set no upper age limit and 3 (8%) stop at 75 or younger. 12 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (8%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
109 (25%)9 (25%)
1835 (97%)35 (97%)
3036 (100%)36 (100%)
4036 (100%)36 (100%)
5036 (100%)36 (100%)
6536 (100%)36 (100%)
7534 (94%)34 (94%)
8530 (83%)30 (83%)

Across all 107 studies, recruiting or not: 8% stop at 75 or younger and 2% at 65; 31% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Paraganglioma studies take

Of 26 phase 2 interventional studies under Paraganglioma, half reached primary completion within 111 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 2111 mo36–157 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 107. Browse all 107 → or search them.